Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2019-01-23 / Cancer Gene Ther. 2019 09;26(9-10):282-291Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer
/in Dendritic Cells, Gastric Cancer, International Publications /von 2019-01-12 / Life Sci. 2019 Feb;219:136-143An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2019-01-07 / Int. J. Cancer 2019 Jun;144(11):2867-2879Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects
/in Breast Cancer, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-01-01 / Crit Rev Immunol 2019;39(3):211-221The Role of the Status of Selected Micronutrients in Shaping the Immune Function
/in International Publications, Micronutrients /von 2019-01-01 / 2019;19(8):1100-1115A pilot study of the impact of Vitamin C supplementation with neoadjuvant chemoradiation on regulators of inflammation and carcinogenesis in esophageal cancer patients
/in International Publications, Micronutrients /von 2019-01-01 / J Cancer Res Ther 2019 Jan-Mar;15(1):185-191A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers
/in Dendritic Cells, International Publications /von 2019-01-01 / Methods Mol. Biol. 2019;1884:317-333Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-01-01 / Klin Onkol 2019;32(1):70-74
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution